Company intelligence / Profile preview
Pelthos Therapeutics
Durham, North Carolina, United Statespelthos.com ↗
- Ownership
- Public · PTHS
- Development stage
- Other
01
Overview
Lead product ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum has been approved by the FDA and is expected to be commercially available in late 2024. It is the first and only approved topical prescription medication that can be applied at home for this highly contagious viral skin infection.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Nitric oxide-based therapeutics
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $35.6M
- Total revenue
- $16.8M
- Enterprise value
- $84.2M
Beyond the preview
Go deeper on Pelthos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pelthos Therapeutics.